ACET

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adicet Bio Inc

NASDAQ | ACET

0.66

USD

$0.00

(

0.00%

)

At Close (As of Nov 6, 2025)

$105.75M

Market Cap

-

P/E Ratio

-1.3

EPS

$1.40

52 Week High

$0.44

52 Week Low

HEALTHCARE

Sector

ACET Chart

Recent Chart
Price Action

ACET Technicals

Tags:

ACET Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.5M
Total Revenue $0
Cost Of Revenue $6.5M
Costof Goods And Services Sold $6.5M
Operating Income -$128M
Selling General And Administrative $28M
Research And Development $99M
Operating Expenses $128M
Investment Income Net -
Net Interest Income $11M
Interest Income $11M
Interest Expense $4K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.5M
Income Before Tax -$117M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$117M
Comprehensive Income Net Of Tax -
Ebit -$117M
Ebitda -$111M
Net Income -$117M

Revenue & Profitability

Earnings Performance

ACET Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $220M
Total Current Assets $180M
Cash And Cash Equivalents At Carrying Value $56M
Cash And Short Term Investments $56M
Inventory -
Current Net Receivables -
Total Non Current Assets $40M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $120M
Other Current Assets $3.8M
Other Non Current Assets -
Total Liabilities $34M
Total Current Liabilities $19M
Current Accounts Payable $4.8M
Deferred Revenue -
Current Debt -
Short Term Debt $6.3M
Total Non Current Liabilities $14M
Capital Lease Obligations $17M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $17M
Other Current Liabilities $8.3M
Other Non Current Liabilities $116K
Total Shareholder Equity $187M
Treasury Stock -
Retained Earnings -$498M
Common Stock $8K
Common Stock Shares Outstanding $88M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$92M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $6.5M
Capital Expenditures $1.1M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$119M
Cashflow From Financing $111M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$117M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.5M
Total Revenue $0
Cost Of Revenue $6.5M
Costof Goods And Services Sold $6.5M
Operating Income -$128M
Selling General And Administrative $28M
Research And Development $99M
Operating Expenses $128M
Investment Income Net -
Net Interest Income $11M
Interest Income $11M
Interest Expense $4K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.5M
Income Before Tax -$117M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$117M
Comprehensive Income Net Of Tax -
Ebit -$117M
Ebitda -$111M
Net Income -$117M

ACET News

ACET Profile

Adicet Bio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adicet Bio, Inc. is an innovative biotechnology company focused on pioneering allogeneic gamma delta T cell therapies aimed at treating cancer and other serious diseases. Headquartered in Boston, Massachusetts, the company leverages its proprietary platform to develop novel immune-oncology solutions, positioning itself at the forefront of cell therapy advancements. With a robust pipeline of candidates in clinical development, Adicet Bio is dedicated to improving patient outcomes through its cutting-edge research and commitment to harnessing the immune system's potential.

NVVE
-8.57%
$0.19
YGMZ
+36.78%
$0.17
WORX
+87.40%
$0.54
ASST
+16.80%
$1.46
RIVN
+23.36%
$15.42
GPUS
+11.61%
$0.39
RUBI
-49.75%
$0.30
VHAI
0.00%
$0.00
BYND
-4.51%
$1.27
PLUG
+4.76%
$2.64
SNAP
-2.27%
$7.30
TSLA
+4.00%
$462.07
CHR
-18.91%
$0.06
YDKG
-5.55%
$0.05
F
+2.50%
$13.11
PLTR
-1.48%
$187.90
AXDX
-61.36%
$0.03
ACHR
+0.10%
$9.57
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
ONDS
+0.67%
$6.00
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
TEVA
+20.23%
$24.60
NFE
+10.37%
$1.49
ADAP
-15.14%
$0.05
DVLT
-10.11%
$1.60
FTEL
+25.17%
$2.77
MARA
+3.06%
$17.13
QS
+10.55%
$17.07
AAPL
+0.03%
$270.14
RIG
0.00%
$3.90
RMBL
+60.50%
$3.21
WULF
+2.33%
$15.36
ADD
-25.47%
$0.05
BURU
+0.20%
$0.29
NVO
+0.43%
$48.46
EPWK
-6.41%
$0.07
NVDA
-1.30%
$192.66
SRM
+53.27%
$10.30
BMNR
+4.96%
$41.42
NCLH
-0.95%
$18.61
PGHL
+13.94%
$0.52
RIOT
-1.58%
$18.97
JOBY
+1.62%
$15.00
MTC
-26.71%
$1.61
NOK
+0.58%
$6.85
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
QBTS
+4.30%
$31.02
GOOGL
+2.43%
$284.31
HOOD
+4.15%
$142.47
IOVA
+28.45%
$2.32
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
IONZ
-7.60%
$4.13
HPE
+0.63%
$23.71
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
ETWO
0.00%
$3.30
PBR
+2.62%
$12.14
ABEV
+1.25%
$2.42
AFMD
-34.94%
$0.18
WTO
-7.66%
$0.04
LAES
+11.33%
$6.58
UPST
-9.71%
$41.75
ZETA
+19.40%
$19.94
BTE
+1.71%
$2.37
AMC
-0.39%
$2.50
CDE
+2.67%
$14.19
KLG
-9.05%
$13.35
UBER
-2.02%
$92.75
KHC
-0.12%
$24.14
TOST
+9.48%
$39.02
GRYP
-10.38%
$1.38
BTG
-4.71%
$3.84
MODV
-25.22%
$0.43
SBUX
+4.12%
$82.88
VTRS
+2.47%
$10.75
FEMY
+22.16%
$0.83
KDLY
+3.16%
$0.80
EOSE
+5.39%
$14.86
FI
-0.69%
$64.00
EZGO
-0.48%
$0.14
RR
-0.49%
$4.03
BE
+9.57%
$141.41
CCTG
-25.83%
$0.61
SLB
+1.19%
$36.54
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
BSFC
0.00%
$0.02
ZAPP
-46.30%
$0.15
RKLB
-0.26%
$56.42
BAC
+1.57%
$53.27
KDP
+0.98%
$26.72
ELAN
-4.00%
$21.60
CX
+2.29%
$10.27
HL
+22.08%
$14.78
KO
-0.21%
$68.51
NVVE
-8.57%
$0.19
YGMZ
+36.78%
$0.17
WORX
+87.40%
$0.54
ASST
+16.80%
$1.46
RIVN
+23.36%
$15.42
GPUS
+11.61%
$0.39
RUBI
-49.75%
$0.30
VHAI
0.00%
$0.00
BYND
-4.51%
$1.27
PLUG
+4.76%
$2.64
SNAP
-2.27%
$7.30
TSLA
+4.00%
$462.07
CHR
-18.91%
$0.06
YDKG
-5.55%
$0.05
F
+2.50%
$13.11
PLTR
-1.48%
$187.90
AXDX
-61.36%
$0.03
ACHR
+0.10%
$9.57
AAL
+6.08%
$13.42
BITF
+5.72%
$4.05
ONDS
+0.67%
$6.00
SOFI
+2.38%
$30.07
RXRX
-0.80%
$4.96
TEVA
+20.23%
$24.60
NFE
+10.37%
$1.49
ADAP
-15.14%
$0.05
DVLT
-10.11%
$1.60
FTEL
+25.17%
$2.77
MARA
+3.06%
$17.13
QS
+10.55%
$17.07
AAPL
+0.03%
$270.14
RIG
0.00%
$3.90
RMBL
+60.50%
$3.21
WULF
+2.33%
$15.36
ADD
-25.47%
$0.05
BURU
+0.20%
$0.29
NVO
+0.43%
$48.46
EPWK
-6.41%
$0.07
NVDA
-1.30%
$192.66
SRM
+53.27%
$10.30
BMNR
+4.96%
$41.42
NCLH
-0.95%
$18.61
PGHL
+13.94%
$0.52
RIOT
-1.58%
$18.97
JOBY
+1.62%
$15.00
MTC
-26.71%
$1.61
NOK
+0.58%
$6.85
APPS
+23.14%
$7.29
CMG
+0.72%
$31.97
QBTS
+4.30%
$31.02
GOOGL
+2.43%
$284.31
HOOD
+4.15%
$142.47
IOVA
+28.45%
$2.32
BW
+28.34%
$4.80
NVTS
-5.73%
$9.86
WLGS
-5.57%
$0.04
IONZ
-7.60%
$4.13
HPE
+0.63%
$23.71
RDHL
+2.77%
$1.11
PLTZ
+2.80%
$6.24
ETWO
0.00%
$3.30
PBR
+2.62%
$12.14
ABEV
+1.25%
$2.42
AFMD
-34.94%
$0.18
WTO
-7.66%
$0.04
LAES
+11.33%
$6.58
UPST
-9.71%
$41.75
ZETA
+19.40%
$19.94
BTE
+1.71%
$2.37
AMC
-0.39%
$2.50
CDE
+2.67%
$14.19
KLG
-9.05%
$13.35
UBER
-2.02%
$92.75
KHC
-0.12%
$24.14
TOST
+9.48%
$39.02
GRYP
-10.38%
$1.38
BTG
-4.71%
$3.84
MODV
-25.22%
$0.43
SBUX
+4.12%
$82.88
VTRS
+2.47%
$10.75
FEMY
+22.16%
$0.83
KDLY
+3.16%
$0.80
EOSE
+5.39%
$14.86
FI
-0.69%
$64.00
EZGO
-0.48%
$0.14
RR
-0.49%
$4.03
BE
+9.57%
$141.41
CCTG
-25.83%
$0.61
SLB
+1.19%
$36.54
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
BSFC
0.00%
$0.02
ZAPP
-46.30%
$0.15
RKLB
-0.26%
$56.42
BAC
+1.57%
$53.27
KDP
+0.98%
$26.72
ELAN
-4.00%
$21.60
CX
+2.29%
$10.27
HL
+22.08%
$14.78
KO
-0.21%
$68.51
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.